-
Writing in the Lancet medical journal, researchers from The International Hepatitis Interventional Therapy Group report a new treatment for chronic HCV infection that uses a combination of interferon alpha-2b and a drug called ribavirin.
BBC: Better treatment for Hepatitis C
-
Currently a drug called interferon alpha-2b is given to patients for a 48-week period.
BBC: Better treatment for Hepatitis C
-
This analysis by Cassidy and other commentators neglects to consider there is an important problem with many of the current job related visas, including H-1B, H-2B, and H-2A: a potential immigrant is not simply permitted to work in this country, but only permitted to work for a specific employer who petitioned for the visa to hire them.
FORBES: How To Improve Immigrant Visas
-
Another concern is the Department of Labor has administrative discretion under the new category, as it has with H-2B visas, a category for seasonal nonagricultural workers.
FORBES: Too Few Work Visas in New Immigration Bill
-
The standard interferon alpha-2b treatment three times a week.
BBC: Better treatment for Hepatitis C
-
However, today, America has only a bureaucratic H-2A visa category that pleases neither growers nor the farm workers union, and a cumbersome H-2B visa for short-term seasonal work outside of agriculture.
FORBES: They Shoot Horses Don't They?
-
Seeking depth for their injury-depleted infield, the Yankees acquired 3B-2B Chris Nelson from Colorado for a player to be named or cash.
WSJ: Cano homers, Yankees hold off Astros 5-4
-
Ventura said 2B Gordon Beckham would play Thursday for Triple-A Charlotte and that he didn't expect him to come back to Chicago until next Thursday.
NPR: Navarro Hits 3 HRs, Cubs Pound White Sox 9-3
-
For its H-2B efforts, Signal International has endured a yearlong nightmare.
FORBES: Labor Unrest
-
Pirates 2B Neil Walker (right hand cut) is starting a rehab assignment with Double-A Altoona.
WSJ: Mets catch up to McCutchen, beat Pirates 3-2
-
With Isis, Symphony and some co-investors are creating a new entity, Symphony GenIsis, that will take ownership of a promising cholesterol-lowering drug candidate in Isis' pipeline through its Phase 2b trials.
FORBES: Biotech's Financial Lifeline